Latest Mast Therapeutics Inc. Stories
SAN DIEGO, May 15, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended March 31, 2013. Brian M. Culley, Chief Executive Officer, said: "We have opened more than a dozen clinical sites in EPIC, our pivotal phase 3 study in sickle cell disease, and are on track to meet our goal of opening approximately 40 U.S. sites by year-end. We also plan to support U.S. enrollment by opening roughly 30 sites outside the U.S.,...
SAN DIEGO, April 17, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that two posters for its lead product candidate, MST-188, were presented at the 7(th) Annual Sickle Cell Disease Research & Educational Symposium, currently underway in Miami. Brian M. Culley, Chief Executive Officer, said: "Increasing evidence suggests that transfusion of 'older' red blood cells (RBC) impairs clinical outcomes as a result of defects resulting from storage or age....
SAN DIEGO, March 28, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has engaged ESC Advisors, a division of the investment banking firm KEMA Partners LLC, to serve as its exclusive financial advisor to identify potential partners for MST-188 and advise the Company in transaction discussions. Brian M. Culley, Chief Executive Officer, said: "Given the high unmet need and limited treatment options, sickle cell disease is experiencing significant...
SAN DIEGO, March 25, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the European Commission (EC) has designated MST-188 as an orphan medicinal product for the treatment of sickle cell disease. This decision follows a positive opinion adopted by the Committee for Orphan Medicinal Products (COMP) recommending such designation. Brian M. Culley, Chief Executive Officer, said: "Now that we actively are recruiting patients in EPIC, our pivotal phase 3...
SAN DIEGO, March 19, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the fourth quarter and year ended December 31, 2012. Brian M. Culley, Chief Executive Officer, said: "2013 will be an exciting year for Mast Therapeutics. We already have accomplished several key objectives, including initiating a pivotal phase 3 clinical study in sickle cell disease, initiating a thorough QT study of MST-188, identifying multiple new development...
SAN DIEGO, March 11, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. today completed its previously announced corporate name change to "Mast Therapeutics, Inc." In addition, effective at the opening of trading today, the Company's new ticker symbol is "MSTX." The Company's common stock is listed on the NYSE MKT. The corporate website is available at www.masttherapeutics.com. The Company's lead product candidate will be referred to as "MST-188" (formerly, ANX-188). A new...
Name and ticker symbol changes effective March 11, 2013 SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that, effective March 11, 2013, its corporate name will be "Mast Therapeutics, Inc." Brian M. Culley, Chief Executive Officer, said: "The new corporate identity we announce today is the final step in a transformational process through which we have changed fundamentally this company's priorities, personnel and business...
